The new oral anticoagulants

Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thromboti...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2010-01, Vol.115 (1), p.15-20
Main Authors: Garcia, David, Libby, Edward, Crowther, Mark A.
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants - administration & dosage
Anticoagulants - pharmacology
Biological and medical sciences
Clinical Trials as Topic
Drug Discovery
Hematologic and hematopoietic diseases
Humans
Medical sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3
cites cdi_FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3
container_end_page 20
container_issue 1
container_start_page 15
container_title Blood
container_volume 115
creator Garcia, David
Libby, Edward
Crowther, Mark A.
description Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant interpatient and intrapatient variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with these agents have led clinicians, patients, and investigators to search for alternative agents. Three new orally administered anticoagulants (apixaban, dabigatran, and rivaroxaban) are in the late stages of development and several others are just entering (or moving through) earlier phases of investigation. These novel anticoagulant medications are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban.
doi_str_mv 10.1182/blood-2009-09-241851
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2009_09_241851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120301014</els_id><sourcerecordid>S0006497120301014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gSK9eFydSbLd7EWQ4hcUvNRzmM1OdGW7W5JW8d8b3aI3YWDm8LzDPCPEGcIlopFXVdv3dSYByiyV1Ghy3BNjzKXJACTsizEAzDJdFjgSRzG-AaBWMj8UIyyNAV3iWJwuX3na8ce0D9ROqds0rqeXbZumeCwOPLWRT3Z9Ip7vbpfzh2zxdP84v1lkTqtik2mQ7L0qSvI5SwPsjYZ0oZcyn5UKVVVLXeeE7KAi4wldTRIKT6yK3JOaCD3sdaGPMbC369CsKHxaBPvtan9c7berTTW4ptj5EFtvqxXXf6GdXAIudgBFR60P1Lkm_nJSqvQNhMRdDxwnyfeGg42u4c5x3QR2G1v3zf-XfAFN5HE8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The new oral anticoagulants</title><source>ScienceDirect Journals</source><creator>Garcia, David ; Libby, Edward ; Crowther, Mark A.</creator><creatorcontrib>Garcia, David ; Libby, Edward ; Crowther, Mark A.</creatorcontrib><description>Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant interpatient and intrapatient variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with these agents have led clinicians, patients, and investigators to search for alternative agents. Three new orally administered anticoagulants (apixaban, dabigatran, and rivaroxaban) are in the late stages of development and several others are just entering (or moving through) earlier phases of investigation. These novel anticoagulant medications are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2009-09-241851</identifier><identifier>PMID: 19880491</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Administration, Oral ; Anticoagulants - administration &amp; dosage ; Anticoagulants - pharmacology ; Biological and medical sciences ; Clinical Trials as Topic ; Drug Discovery ; Hematologic and hematopoietic diseases ; Humans ; Medical sciences</subject><ispartof>Blood, 2010-01, Vol.115 (1), p.15-20</ispartof><rights>2010 American Society of Hematology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3</citedby><cites>FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120301014$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27901,27902,45756</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22332510$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19880491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcia, David</creatorcontrib><creatorcontrib>Libby, Edward</creatorcontrib><creatorcontrib>Crowther, Mark A.</creatorcontrib><title>The new oral anticoagulants</title><title>Blood</title><addtitle>Blood</addtitle><description>Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant interpatient and intrapatient variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with these agents have led clinicians, patients, and investigators to search for alternative agents. Three new orally administered anticoagulants (apixaban, dabigatran, and rivaroxaban) are in the late stages of development and several others are just entering (or moving through) earlier phases of investigation. These novel anticoagulant medications are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban.</description><subject>Administration, Oral</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Anticoagulants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Drug Discovery</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Medical sciences</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlZ_gSK9eFydSbLd7EWQ4hcUvNRzmM1OdGW7W5JW8d8b3aI3YWDm8LzDPCPEGcIlopFXVdv3dSYByiyV1Ghy3BNjzKXJACTsizEAzDJdFjgSRzG-AaBWMj8UIyyNAV3iWJwuX3na8ce0D9ROqds0rqeXbZumeCwOPLWRT3Z9Ip7vbpfzh2zxdP84v1lkTqtik2mQ7L0qSvI5SwPsjYZ0oZcyn5UKVVVLXeeE7KAi4wldTRIKT6yK3JOaCD3sdaGPMbC369CsKHxaBPvtan9c7berTTW4ptj5EFtvqxXXf6GdXAIudgBFR60P1Lkm_nJSqvQNhMRdDxwnyfeGg42u4c5x3QR2G1v3zf-XfAFN5HE8</recordid><startdate>20100107</startdate><enddate>20100107</enddate><creator>Garcia, David</creator><creator>Libby, Edward</creator><creator>Crowther, Mark A.</creator><general>Elsevier Inc</general><general>Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100107</creationdate><title>The new oral anticoagulants</title><author>Garcia, David ; Libby, Edward ; Crowther, Mark A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Anticoagulants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Drug Discovery</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Medical sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia, David</creatorcontrib><creatorcontrib>Libby, Edward</creatorcontrib><creatorcontrib>Crowther, Mark A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia, David</au><au>Libby, Edward</au><au>Crowther, Mark A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The new oral anticoagulants</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2010-01-07</date><risdate>2010</risdate><volume>115</volume><issue>1</issue><spage>15</spage><epage>20</epage><pages>15-20</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant interpatient and intrapatient variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with these agents have led clinicians, patients, and investigators to search for alternative agents. Three new orally administered anticoagulants (apixaban, dabigatran, and rivaroxaban) are in the late stages of development and several others are just entering (or moving through) earlier phases of investigation. These novel anticoagulant medications are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>19880491</pmid><doi>10.1182/blood-2009-09-241851</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2010-01, Vol.115 (1), p.15-20
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2009_09_241851
source ScienceDirect Journals
subjects Administration, Oral
Anticoagulants - administration & dosage
Anticoagulants - pharmacology
Biological and medical sciences
Clinical Trials as Topic
Drug Discovery
Hematologic and hematopoietic diseases
Humans
Medical sciences
title The new oral anticoagulants
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A58%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20new%20oral%20anticoagulants&rft.jtitle=Blood&rft.au=Garcia,%20David&rft.date=2010-01-07&rft.volume=115&rft.issue=1&rft.spage=15&rft.epage=20&rft.pages=15-20&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2009-09-241851&rft_dat=%3Celsevier_cross%3ES0006497120301014%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-402eff379af5e280ef840182f22569313bd24d5a1ec0ba8fa1cda207fae375fa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19880491&rfr_iscdi=true